Philippe Charron

List of Publications by Year
in descending order

42 papers	10,211 citations	257429 24 h-index	265191 42 g-index
44 all docs	44 docs citations	44 times ranked	10239 citing authors

#	Article	IF	Citations
1	2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy. European Heart Journal, 2014, 35, 2733-2779.	2.2	3,469
2	Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseases. European Heart Journal, 2007, 29, 270-276.	2.2	2,280
3	Hypertrophic Cardiomyopathy. Circulation, 2003, 107, 2227-2232.	1.6	1,129
4	Proposal for a revised definition of dilated cardiomyopathy, hypokinetic non-dilated cardiomyopathy, and its implications for clinical practice: a position statement of the ESC working group on myocardial and pericardial diseases. European Heart Journal, 2016, 37, 1850-1858.	2.2	757
5	A genome-wide association study identifies two loci associated with heart failure due to dilated cardiomyopathy. European Heart Journal, 2011, 32, 1065-1076.	2.2	292
6	Clinical Features and Prognostic Implications of Familial Hypertrophic Cardiomyopathy Related to the Cardiac Myosin-Binding Protein C Gene. Circulation, 1998, 97, 2230-2236.	1.6	241
7	Long-Term Arrhythmic and Nonarrhythmic Outcomes of Lamin A/C Mutation Carriers. Journal of the American College of Cardiology, 2016, 68, 2299-2307.	2.8	215
8	Hypertrophic obstructive cardiomyopathy. Lancet, The, 2017, 389, 1253-1267.	13.7	188
9	Clinical Diagnosis, Imaging, and Genetics of Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Journal of the American College of Cardiology, 2018, 72, 784-804.	2.8	188
10	Genetic advances in sarcomeric cardiomyopathies: state of the art. Cardiovascular Research, 2015, 105, 397-408.	3.8	187
11	Shared genetic pathways contribute to risk of hypertrophic and dilated cardiomyopathies with opposite directions of effect. Nature Genetics, 2021, 53, 128-134.	21.4	155
12	A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. European Heart Journal, 2014, 35, 1069-1077.	2.2	137
13	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Europace, 2022, 24, 1307-1367.	1.7	108
14	The Cardiomyopathy Registry of the EURObservational Research Programme of the European Society of Cardiology: baseline data and contemporary management of adult patients with cardiomyopathies. European Heart Journal, 2018, 39, 1784-1793.	2.2	94
15	Exome-wide association study reveals novel susceptibility genes to sporadic dilated cardiomyopathy. PLoS ONE, 2017, 12, e0172995.	2.5	92
16	European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the State of Genetic Testing for Cardiac Diseases. Heart Rhythm, 2022, 19, e1-e60.	0.7	78
17	Role of Genetic Testing in Inherited Cardiovascular Disease. JAMA Cardiology, 2017, 2, 1153.	6.1	75
18	Natural genetic variation of the cardiac transcriptome in non-diseased donors and patients with dilated cardiomyopathy. Genome Biology, 2017, 18, 170.	8.8	70

#	Article	IF	Citations
19	FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotypeâ€phenotype correlations. Clinical Genetics, 2019, 96, 317-329.	2.0	63
20	European Cardiomyopathy Pilot Registry: EURObservational Research Programme of the European Society of Cardiology. European Heart Journal, 2016, 37, 164-173.	2.2	56
21	Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23. European Heart Journal, 2021, 42, 2000-2011.	2.2	49
22	Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging. European Heart Journal, 2010, 31, 1599-1607.	2.2	36
23	Pregnancy in women with a cardiomyopathy: Outcomes and predictors from a retrospective cohort. Archives of Cardiovascular Diseases, 2018, 111, 199-209.	1.6	32
24	Clinical Profile of Cardiac Involvement in Danon Disease. Circulation Genomic and Precision Medicine, 2020, 13, e003117.	3.6	29
25	European Heart Rhythm Association (<scp>EHRA</scp>)/Heart Rhythm Society (<scp>HRS</scp>)/Asia Pacific Heart Rhythm Society (<scp>APHRS</scp>)/Latin American Heart Rhythm Society (<scp>LAHRS</scp>) Expert Consensus Statement on the state of genetic testing for cardiac diseases. Journal of Arrhythmia, 2022, 38, 491-553.	1.2	24
26	Differences between familial and sporadic dilated cardiomyopathy: ESC EORP Cardiomyopathy & Myocarditis registry. ESC Heart Failure, 2021, 8, 95-105.	3.1	23
27	Involvement of BAG3 and HSPB7 loci in various etiologies of systolic heart failure: Results of a European collaboration assembling more than 2000 patients. International Journal of Cardiology, 2015, 189, 105-107.	1.7	22
28	Clinical impact of post-mortem genetic testing in cardiac death and cardiomyopathy. Open Medicine (Poland), 2020, 15, 435-446.	1.3	12
29	The Public Health Burden of Cardiomyopathies: Insights from a Nationwide Inpatient Study. Journal of Clinical Medicine, 2020, 9, 920.	2.4	11
30	Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry. European Heart Journal Quality of Care & Clinical Outcomes, 2022, 9, 42-53.	4.0	11
31	Global and regional echocardiographic strain to assess the early phase of hypertrophic cardiomyopathy due to sarcomeric mutations. European Heart Journal Cardiovascular Imaging, 2020, 21, 291-298.	1.2	10
32	Phenotype/Genotype Relationship in Left Ventricular Noncompaction: Ion Channel Gene Mutations Are Associated With Preserved Left Ventricular Systolic Function and Biventricular Noncompaction. Journal of Cardiac Failure, 2021, 27, 677-681.	1.7	10
33	Psychosocial Impact of Predictive Genetic Testing in Hereditary Heart Diseases: The PREDICT Study. Journal of Clinical Medicine, 2020, 9, 1365.	2.4	9
34	A novel risk model for predicting potentially life-threatening arrhythmias in non-ischemic dilated cardiomyopathy (DCM-SVA risk). International Journal of Cardiology, 2021, 339, 75-82.	1.7	9
35	Generation of iPSC line from MYH7 R403L mutation carrier with severe hypertrophic cardiomyopathy and isogenic CRISPR/Cas9 corrected control. Stem Cell Research, 2021, 52, 102245.	0.7	8
36	Recommendations for the diagnosis and management of hypertrophic cardiomyopathy in 2014. Archives of Cardiovascular Diseases, 2015, 108, 151-155.	1.6	6

#	Article	IF	Citations
37	Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy. Heart, 2019, 106, heartjnl-2019-314826.	2.9	5
38	Prevalence of familial hypercholesterolaemia in patients presenting with premature acute coronary syndrome. Archives of Cardiovascular Diseases, 2022, 115, 87-95.	1.6	5
39	Higher prevalence of splenic artery aneurysms in hereditary hemorrhagic telangiectasia: Vascular implications and risk factors. PLoS ONE, 2020, 15, e0226681.	2.5	4
40	Assessment of atrial function by myocardial deformation techniques in hypertrophic cardiomyopathy. Echocardiography, 2021, 38, 230-237.	0.9	1
41	European Reference Network for rare, low prevalence, or complex diseases of the heart (ERN) Tj ETQq1 1 0.784314 rgBT /Overlock 10	2.2	1
42	Generation of a heterozygous SCN5A knockout human induced pluripotent stem cell line by CRISPR/Cas9 edition. Stem Cell Research, 2022, 60, 102680.	0.7	0